Thursday 21 November – Friday 22 November 2024
We are delighted to invite you to this year’s ACP trainee meeting. This year’s meeting has the theme of “Precision Oncology”.
Cancer treatment is becoming increasingly tailored to the individual patient, with an ever increasing number of targeted therapies. Our programme will explore the role of molecularly targeted therapies and individually tailored treatments in a variety of tumour sites. In addition, we will be hearing about the future of Precision Oncology and personalised treatment in the form of cancer vaccines, ctDNA guided therapy, whole genome sequencing and cellular therapies. We have a range of speakers from across the UK, all of whom are experts in their fields, and we believe that this will be an incredibly interesting and educational meeting.
For the first time for an ACP trainee meeting, we have had to include a small fee for attendance. Although we are grateful to our sponsors for their generous support, the costs of running these events are considerable, and we are no longer able to hold the meeting without asking for a contribution from attendees. However, we believe that this cost still represents good value for money and is still below that charged for similar events by other organisations.
Venue
Venue: Hilton Leeds City Hotel, Leeds.
Fees:
Meeting Only (no accommodation) – £50
Meeting + Accommodation – £100
Note: This event is only open to ACP Trainee Members.
Click here to become a Member.
Accommodation
Complimentary Thursday night accommodation is offered to trainees and can be booked via the registration site. A preferential rate of £130 has been secured for the Wednesday night. This can be booked via the link sent to you in your booking confirmation email.
Speakers
Click here to download the speaker biographies. Speakers’ presentations are available in the programme below.
Programme
Click here to download the programme.
| Thursday 21 November 2024 | ||
| 0930 – 0950 | Registration with coffee | |
| 0950 | Welcome and introduction – Dr Richard Heywood, Chair, ACP Trainee Committee | |
| 1000 | Session 1: Cancer Vaccines – Now and in the future Dr Dan Muller and Patrick Ezeani, Cancer Vaccines Launchpad Team | |
| 1100 | REFRESHMENT BREAK | |
| 1130 | Session 2: Precision oncology and targeted therapies: gynaecological cancers Dr Rowan Miller, UCL | |
| 1215 | Precision oncology and targeted therapies: renal cancer Dr Naveen Vasudev, Leeds Cancer Centre | |
| 1300 | NETWORKING LUNCH | |
| 1400 | Session 3: Precision oncology and targeted therapies: lung cancer Dr Adam Januszewski, St Barts Hospital, London | |
| 1445 | Precision oncology and targeted therapies: triple negative breast cancer Professor Chris Twelves, Leeds | |
| 1530 | REFRESHMENT BREAK | |
| 1600 | Session 4: ctDNA guided treatment (focus on melanoma and GI cancers) Dr Rebecca Lee, Christie and Dr Chris Williams, Leeds Teaching Hospitals | |
| 1700-1745 | National Oncology Trainee Collaborative for Healthcare Research (NOTCH) Dr Karin Purshouse, NOTCH chair | |
| 1930 – 0000 | Dinner | |
| Friday 22 November 2024 | ||
| 0800-0830 | Registration with coffee | |
| 0830 | Session 5: ACP Trainee Update ACP Trainee Committee | |
| 0915 | Session 6: Breast Cancer: Tailoring treatments based on pathological response Dr Caroline Michie, Edinburgh Cancer Centre | |
| 1000 | REFRESHMENT BREAK | |
| 1030 | Session 7: BAGSHAWE LECTURE Whole Genome Sequencing in Oncology: Current landscape and future directions Professor Carlos Caldas, University of Cambridge | |
| 1130 | CAR-T and cellular therapies Dr Maise Al-Bakir, UCLH | |
| 1215 | Precision oncology and targeted therapies: melanoma Dr Heather Shaw, UCLH | |
| 1300 | NETWORKING LUNCH | |
| 1400 | Session 8: Precision oncology and targeted therapies: GI cancers Dr Kai-Keen Shiu, UCLH | |
| 1500 | ACP Prize Presentations Discovery of The Lymphocyte Stability Index: a pan-cancer biomarker for response to immune checkpoint blockade Dr Robert Watson, President’s Prize winner 2023 Identification of novel therapeutic targets in uveal melanoma using CRISPR-Cas9 Dr Jenny Pui Ying Chan, McElwain’s Prize: Translational winner PD-L1 imaging in NSCLC Dr Daniel Hughes, McElwain’s Prize: Clinical winner | |
| 1545 | Closing Remarks Dr Richard Heywood, Chair, ACP Trainee Committee | |
| 1600 | End of conference | |
Sponsors
Amgen’s mission is to serve patients. A biotechnology innovator since 1980, our science-based heritage is at the heart of everything we do. We develop medicines for hard-to-treat illnesses in areas of high unmet need, to not only help patients, but also reduce the social and economic burden of disease in society. As a regional hub, we employ around 600 people in the UK and Ireland across our commercial, R&D, and corporate functions. Committed to driving sustainable solutions that can adapt to an ever-evolving health system, we are proud to serve our patients, people, and customers every day.
BioNTech is a global immunotherapy company pioneering novel therapies for cancer and other serious diseases. It exploits an array of therapeutic drug platforms for the development of novel biopharmaceuticals. Its portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.
Merck is a science-led organization of curious minds dedicated to delivering transformative medicines that can make a difference in the lives of people affected by cancer. Merck Oncology are on a mission to apply our scientific curiosity and dedication to patients to improving the futures of people living with cancer. We have a vision for a world where more cancer patients can become cancer survivors. Together, We Are Oncology & we are on it!
At Novartis UK, our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues and we work together with the system to implement solutions that drive access for UK patients. From research to delivery, we are a valued partner in the healthcare ecosystem, supporting in times of crisis and beyond, to build solutions that provide better care and access opportunities for every patient in the UK.
For 175 years, Pfizer has been a trusted partner in healthcare – discovering, developing, and delivering medicines to tackle some of the world’s most vexing conditions and diseases. Fast forward to today, we continue to research numerous therapy areas, but with a renewed focus on one of the biggest threats of our time, cancer.
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of people living with cancer.
Our areas of focus include some of the world’s most common cancers, including breast cancer, genitourinary cancer, haematology-oncology, and lung cancer.
Today, we have a portfolio of over 20 approved cancer medicines and biosimilars in the UK.
Our ambitions have accelerated over the past 175 years, but we will continue to celebrate our legacy, whilst pushing forward for the patients that we serve and setting our sights on changing a billion lives a year by 2027. Looking ahead, motivation, today, isn’t to stay the course – it’s to outdo yesterday.
At Roche UK, we focus our energy and investment in developing tests and treatments that change lives and give us more quality time with the people we love. And, together with others, we’re solving healthcare’s greatest challenges; helping to achieve better results by connecting early diagnosis to targeted treatment and ongoing support.
Healthcare matters to all of us. That’s why we work hard to ensure that all our new medicines are made available to those who need them through the NHS – wherever they live, whatever their circumstances.
In 2020, more than 820 million Roche diagnostic tests were used to confirm, rule out or manage health conditions and over 712,000 patients benefited from our medicines and diabetes monitoring and insulin delivery system. During this period, we contributed £1.26 billion to the UK economy, supporting over 21,000 jobs.
Proud of what we do, we’re here because we care. In the UK we employ over 2,000 brilliant specialists who work together to transform the lives of patients and their loved ones.
That’s what makes us who we are. That’s what makes us Roche UK. For more information, please visit www.roche.co.uk.
At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere.
Delivering on the unique needs of patients, who have limited or ineffective treatment options, is at the centre of everything we do. We live this philosophy by putting patient needs first, building trust with society, strengthening our reputation, and delivering the business – in that order. We strive to provide transformative therapies, developed from ground-breaking science, to dramatically improve patients’ lives.